High Grade B Cell Lymphoma Double Hit Triple Hit Cn324017
An aggressive lymphoma with multiple genetic rearrangements, known as double or triple hit lymphoma. It requires prompt, intensive treatment due to rapid progression.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Rapidly growing lymph node masses
Fever
Spinal cord compression
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Bone pain
(Musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensive Chemotherapy Regimen
Multi-agent chemotherapy using regimens such as DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) is the primary treatment approach for double-hit/triple-hit lymphomas, often combined with CNS prophylaxis.
Medication management with follow-up
Active treatment with regular monitoring by a healthcare provider is recommended.
Autologous Stem Cell Transplantation
High-dose chemotherapy followed by autologous stem cell rescue is considered for patients who achieve remission, particularly for those with high-risk features or suboptimal response to initial therapy.
Additional treatment options
Targeted Therapy with BTK Inhibitors
BTK inhibitors such as ibrutinib may be incorporated into treatment regimens, particularly in relapsed/refractory settings or as part of combination approaches, targeting the B-cell receptor signaling pathway.
medicationConsolidation Radiation Therapy
Involves targeted radiation to sites of initial bulky disease or residual masses after chemotherapy, particularly for extranodal involvement, to improve local control rates.
procedureSurveillance and Response Assessment
Regular imaging with PET-CT scans and periodic CT imaging, along with laboratory monitoring, to assess treatment response and detect early relapse in high-risk disease.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is High Grade B Cell Lymphoma Double Hit Triple Hit Cn324017?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat High Grade B Cell Lymphoma Double Hit Triple Hit Cn324017. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy